Heart Attack Cell Therapy Gets $6.9 Million

How Could Cell Therapy Repair Damage After a Heart Attack?

USC's investigational treatment uses stem-cell-derived heart muscle cells intended for patients with severe heart attacks complicated by cardiogenic shock. The planned product would be manufactured in advance rather than individually customized. Its initial version would require immune-suppressing medicines to prevent rejection. These details come from a university announcement, not results demonstrating effectiveness in patients. [USC research announcement](https://www.brightsurf.com/news/LN24W291/cirm-awards-69-million-to-move-cell-therapy-for-heart-attack-to-clinical-trials.html).

The biological challenge is substantial. When a heart attack interrupts blood supply, muscle cells can die, and damaged tissue heals by forming scar. Scar tissue does not contract as effectively as healthy muscle, potentially leaving the heart with reduced pumping capacity. Replacing lost muscle could therefore address an important source of lasting disability, but that possibility must be established experimentally. [American Heart Association](https://www.heart.org/en/health-topics/heart-attack/about-heart-attacks).

What Must Happen Before Researchers Can Test the Treatment in Patients?

The award supports work on product consistency, manufacturing and final animal studies. Researchers plan to seek FDA clearance for an initial safety and feasibility trial at USC and the University of Washington. Funding and a proposed start date do not establish that treatment is ready for routine care. [USC research announcement](https://www.brightsurf.com/news/LN24W291/cirm-awards-69-million-to-move-cell-therapy-for-heart-attack-to-clinical-trials.html).

Earlier research illustrates why clinical outcomes matter. A Cochrane review published in 2024 examined 53 randomized trials involving 4,159 participants who received their own bone-marrow-derived cells or a comparison treatment after a heart attack. It found no reduction in mortality, despite some improvements in measurements of heart pumping function. Those findings concern a different cell treatment and cannot determine whether USC's approach will work. They do, however, support a crucial distinction: a better imaging measurement does not automatically mean longer survival or fewer hospital admissions. [Cochrane review](https://www.cochrane.org/evidence/CD006536_are-stem-cells-taken-persons-bone-marrow-and-delivered-their-heart-safe-and-effective-treatment).

What Does This Research Mean for Heart Attack Treatment Today?

Established emergency treatment can limit heart muscle injury and save lives. Depending on the circumstances, clinicians reopen a blocked coronary artery using angioplasty and a stent, or use clot-dissolving medicines when timely angioplasty is unavailable. Antiplatelet medicines help prevent additional clotting. Any future regenerative treatment would need to demonstrate benefit alongside appropriate existing care. [National Heart, Lung, and Blood Institute](https://www.nhlbi.nih.gov/health/heart-attack/treatment).

Recovery also involves prescribed medicines and, when appropriate, cardiac rehabilitation. Rehabilitation combines supervised exercise, education and support for returning to daily activities. Medicines may include cholesterol-lowering treatment, antiplatelets and therapies that reduce the heart's workload, tailored to the individual's condition. Patients should continue their prescribed treatment while experimental approaches are evaluated. [NHLBI recovery guidance](https://www.nhlbi.nih.gov/health/heart-attack/recovery).